G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-213-9835
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees84
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.69) by $0.05. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
8 brokers have issued 12-month target prices for G1 Therapeutics' shares. Their predictions range from $41.00 to $80.00. On average, they expect G1 Therapeutics' share price to reach $66.00 in the next twelve months. This suggests a possible upside of 156.8% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
Has G1 Therapeutics been receiving favorable news coverage?
Media coverage about GTHX stock has trended neutral this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. G1 Therapeutics earned a media sentiment score of 0.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for G1 Therapeutics.
Are investors shorting G1 Therapeutics?
G1 Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 3,673,600 shares, an increase of 8.2% from the May 15th total of 3,395,700 shares. Based on an average daily trading volume, of 437,500 shares, the short-interest ratio is presently 8.4 days. Approximately 14.2% of the shares of the stock are sold short. View G1 Therapeutics' Current Options Chain.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), The Medicines (MDCO), Uniqure (QURE), Reata Pharmaceuticals (RETA) and PTC Therapeutics (PTCT).
What other stocks do shareholders of G1 Therapeutics own?
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
- Mr. James Stillman Hanson, Gen. Counsel (Age 47)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
- Mr. John Demaree, Chief Commercial Officer (Age 52)
- Ms. Jennifer K. Moses, Chief Financial Officer (Age 44)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $25.70.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $962.98 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
